OncBioMune Selects Theradex as CRO for Two Phase 2 Trials of ProscaVax for Prostate Cancer
08 mars 2018 09h15 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., March 08, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Submits Phase 2 Protocol to Urology Centers of North Texas
28 févr. 2018 08h29 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., Feb. 28, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Provides Updates on two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer
26 févr. 2018 12h47 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., Feb. 26, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Provides Update on Market Activity
16 févr. 2018 16h23 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., Feb. 16, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Signs Letter of Intent to Initiate Phase 2 Trial of ProscaVax for Advanced Prostate Cancer with Urology Clinics of North Texas
05 févr. 2018 08h45 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., Feb. 05, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
70% of Advanced Prostate Cancer Patients Treated with ProscaVax Demonstrate Improvement in PSA Doubling Time
10 janv. 2018 09h20 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., Jan. 10, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial
21 déc. 2017 11h26 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., Dec. 21, 2017 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the...
100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression
05 déc. 2017 08h29 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., Dec. 05, 2017 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the...
80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up
13 nov. 2017 08h25 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., Nov. 13, 2017 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the...
OncBioMune Preparing to Initiate Trials of Novel Therapeutic Ovarian Cancer Vaccine
17 oct. 2017 09h07 HE
|
OncBioMune, L.L.C.
BATON ROUGE, La., Oct. 17, 2017 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the...